• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vbi Vaccines Inc CS (NQ: VBIV )

    0.5710 +0.0070 (+1.24%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 115,872
    Open 0.5471
    Bid (Size) 0.5403 (10)
    Ask (Size) 0.5698 (1)
    Prev. Close 0.5640
    Today's Range 0.5400 - 0.5710
    52wk Range 0.4500 - 3.470
    Shares Outstanding 28,432,275
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023
    VBIV stock results show that VBI Vaccines beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    VBI Vaccines Reports Full Year 2023 Financial Results
    From VBI Vaccines Inc.
    Via Business Wire

    Performance

    YTD
    -7.32%
    -7.32%
    1 Month
    -7.62%
    -7.62%
    3 Month
    -18.45%
    -18.45%
    6 Month
    -3.24%
    -3.24%
    1 Year
    -80.38%
    -80.38%

    More News

    Read More
    VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From VBI Vaccines Inc.
    Via Business Wire
    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From VBI Vaccines Inc.
    Via Business Wire
    Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
    From VBI Vaccines Inc.
    Via Business Wire
    Why Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
    From VBI Vaccines Inc.
    Via Business Wire
    Why Faraday Future Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Reports Third Quarter 2023 Financial Results
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
    From VBI Vaccines Inc.
    Via Business Wire
    Stocks That Hit 52-Week Lows On Thursday
    Via Benzinga
    Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
    From VBI Vaccines Inc.
    Via Business Wire
    Stocks That Hit 52-Week Lows On Thursday
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
    Via Benzinga
    VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
    From VBI Vaccines Inc.
    Via Business Wire
    Stocks That Hit 52-Week Lows On Friday
    Via Benzinga
    VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Reports Second Quarter 2023 Financial Results
    From VBI Vaccines Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.